Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04692545
Other study ID # REGISTROSPERIMENTAZIONI /21
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2016
Est. completion date June 1, 2020

Study information

Verified date December 2020
Source University of Rome Tor Vergata
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Immunonutrition (IN) appears to reduce infective complications and in-hospital length of stay (LOS) after gastrointestinal surgery. More specifically, it seems to be beneficial also in colorectal cancer surgery. Potential benefits of combining preoperative IN (PIN) with protocols of enhanced recovery after surgery (ERAS) in reducing LOS in laparoscopic surgery are yet to be determined.


Recruitment information / eligibility

Status Completed
Enrollment 173
Est. completion date June 1, 2020
Est. primary completion date December 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - laparoscopic colorectal resection for cancer following ERAS protocol - >18 years old - elective setting Exclusion Criteria: - age below 18 - malnutrition - inflammatory bowel disease - acquired or congenital immunodeficiency - preoperative infection - ASA IV - pregnancy - emergency setting - conversion to open surgery - multivisceral resections

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Immunonutrition
nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Rome Tor Vergata

Outcome

Type Measure Description Time frame Safety issue
Primary Length of hospital stay number of days between primary colorectal resection and discharge up to 30 days after discharge
Secondary Time to postoperative food intake number of days between primary colorectal resection and refeeding up to 30 days after discharge
Secondary Time to first defecation number of days between primary colorectal resection and first defecation up to 30 days after discharge
Secondary 30-days postoperative complications Rate of any complication after colorectal resection up to 30 days after discharge
Secondary Surgical site infection rate of any surgical site infection clinically demonstrated up to 30 days after discharge
Secondary Anastomotic leak rate of any postoperative leakage of colo-rectal, colo-colic or ileo-colic anastomosis, clinically, radiologically or endoscopically demonstrated up to 30 days after discharge
Secondary Readmission Rate of any unplanned readmission after discharge up to 90 days after discharge
Secondary 30-days Mortality Rate of any mortality up to 30 days after discharge
Secondary Pneumonia rate of radiologically demonstrated pneumonia up to 30 days after discharge
Secondary Ileus rate of any ileus clinically demonstrated up to 30 days after discharge
Secondary Prolonged length of stay rate of any patient discharged after 8 days up to 30 days after discharge
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A